{"id":"https://openalex.org/A5017897332","orcid":"https://orcid.org/0009-0009-2749-2782","observed_orcids":["https://orcid.org/0009-0009-2749-2782"],"display_name":"Olivier R. Barbeau","raw_author_names":["O. Barbeau","Olivier R. Barbeau","Olivier Re\u0301mi Barbeau"],"full_name":"Olivier R. Barbeau","works_count":3,"cited_by_count":9,"summary_stats":{"2yr_mean_citedness":0.0,"h_index":2,"i10_index":0},"ids":{"openalex":"https://openalex.org/A5017897332","orcid":"https://orcid.org/0009-0009-2749-2782","observed_orcids":["https://orcid.org/0009-0009-2749-2782"]},"affiliations":[{"institution":{"id":"https://openalex.org/I4210148098","ror":"https://ror.org/04qvy9k41","display_name":"Evotec (United Kingdom)","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210130816","https://openalex.org/I4210148098"]},"years":[2026]}],"last_known_institutions":[{"id":"https://openalex.org/I4210148098","ror":"https://ror.org/04qvy9k41","display_name":"Evotec (United Kingdom)","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210130816","https://openalex.org/I4210148098"]}],"topics":[{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","count":3,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","count":2,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","count":1,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","count":1,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","count":1,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"topic_share":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","value":4.28e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","value":8e-06,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","value":7.4e-06,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","value":4.4e-06,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","value":3.9e-06,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"x_concepts":[{"id":"207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","score":0.5678167939186096},{"id":"2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","score":0.5152750015258789},{"id":"121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","score":0.5099629163742065},{"id":"29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","score":0.5077870488166809},{"id":"126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","score":0.21195951104164124}],"counts_by_year":[{"year":2022,"works_count":2,"oa_works_count":1,"cited_by_count":0},{"year":2024,"works_count":0,"oa_works_count":0,"cited_by_count":3},{"year":2025,"works_count":0,"oa_works_count":0,"cited_by_count":2},{"year":2026,"works_count":1,"oa_works_count":0,"cited_by_count":4}],"display_name_alternatives":["O. Barbeau","Olivier R. Barbeau","Olivier Re\u0301mi Barbeau"],"block_key":"o barbeau","works_api_url":"https://api.openalex.org/works?filter=author.id:A5017897332","awards_count":0,"updated_date":"2026-11-04T11:47:51","created_date":"2022-06-16T00:00:00"}